» Articles » PMID: 11119572

Pseudopackaging of Adenovirus Type 5 Genomes into Capsids Containing the Hexon Proteins of Adenovirus Serotypes B, D, or E

Overview
Journal J Virol
Date 2000 Dec 19
PMID 11119572
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Adenoviruses (Ad) show promise as a vector system for gene delivery in vivo. However, a major challenge in the development of Ad vectors is the circumvention of the host immune responses to Ad infection, including both the host cytotoxic T-cell response and the humoral response resulting in neutralizing antibodies. One method to circumvent the effect of neutralizing antibodies against an Ad vector is to use different Ad serotypes to deliver the transgene of interest. This approach has been demonstrated with Ad genomes of highly related members of subgroup C. However, it is not known whether an Ad5-based vector DNA molecule can be packaged into capsids of evolutionarily more divergent adenoviruses. The aim of these studies was to determine if capsids containing hexon proteins from other Ad subgroups could package the Ad5 genome. A genetic approach utilizing an Ad5 temperature-sensitive (ts) mutant with a mutation in the hexon protein was used. When grown at the nonpermissive temperature, Ad5 ts147 replicates normally, providing a source of Ad5 DNA for virus assembly, but does not produce virus particles due to the hexon protein mutation. Coinfection of Ad5 ts147 with a wild-type virus of other Ad serotypes (Ad3, Ad4, or Ad9), which supply functional hexon proteins, resulted in the pseudopackaging of the Ad5 DNA genome. Furthermore, the pseudopackaged Ad5 DNA virions obtained in the coinfections were infectious. Therefore, switching hexons did not impair the infectivity or uncoating process of the pseudopackaged virion. Since hexon protein is a major antigenic determinant of the Ad capsid, this approach may prove useful to reduce the antigenicity of therapeutic Ad vectors and allow repeated vector administration.

Citing Articles

Prion-like Domains in Eukaryotic Viruses.

Tetz G, Tetz V Sci Rep. 2018; 8(1):8931.

PMID: 29895872 PMC: 5997743. DOI: 10.1038/s41598-018-27256-w.


The adenovirus major core protein VII is dispensable for virion assembly but is essential for lytic infection.

Ostapchuk P, Suomalainen M, Zheng Y, Boucke K, Greber U, Hearing P PLoS Pathog. 2017; 13(6):e1006455.

PMID: 28628648 PMC: 5491326. DOI: 10.1371/journal.ppat.1006455.


Components of Adenovirus Genome Packaging.

Ahi Y, Mittal S Front Microbiol. 2016; 7:1503.

PMID: 27721809 PMC: 5033970. DOI: 10.3389/fmicb.2016.01503.


Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.

Lopez-Gordo E, Podgorski I, Downes N, Alemany R Hum Gene Ther. 2014; 25(4):285-300.

PMID: 24499174 PMC: 3997092. DOI: 10.1089/hum.2013.228.


Tropism-modification strategies for targeted gene delivery using adenoviral vectors.

Coughlan L, Alba R, Parker A, Bradshaw A, McNeish I, Nicklin S Viruses. 2011; 2(10):2290-2355.

PMID: 21994621 PMC: 3185574. DOI: 10.3390/v2102290.


References
1.
Kochanek S . High-capacity adenoviral vectors for gene transfer and somatic gene therapy. Hum Gene Ther. 1999; 10(15):2451-9. DOI: 10.1089/10430349950016807. View

2.
Parks R, Evelegh C, Graham F . Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Ther. 1999; 6(9):1565-73. DOI: 10.1038/sj.gt.3300995. View

3.
Moffatt S, Hays J, HogenEsch H, Mittal S . Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy. Virology. 2000; 272(1):159-67. DOI: 10.1006/viro.2000.0350. View

4.
Rux J, Burnett R . Type-specific epitope locations revealed by X-ray crystallographic study of adenovirus type 5 hexon. Mol Ther. 2000; 1(1):18-30. DOI: 10.1006/mthe.1999.0001. View

5.
Norrby E . The structural and functional diversity of Adenovirus capsid components. J Gen Virol. 1969; 5(2):221-36. DOI: 10.1099/0022-1317-5-2-221. View